Xanamem™

DRUG2 trials

Sponsors

Actinogen Medical

Conditions

Cognitive ImpairmentDementia, Alzheimer TypeMDDMajor Depressive Disorder

Phase 2

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

CompletedNCT02727699

Actinogen MedicalDementia, Alzheimer Type

Start: 2017-03-23End: 2019-03-15Updated: 2025-02-03

Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)

CompletedNCT05657691

Actinogen MedicalCognitive Impairment, Major Depressive Disorder, MDD

Start: 2022-11-28End: 2024-07-01Updated: 2025-01-22